Skip to main content

Table 1 Ongoing clinical trials of immunotherapeutic interventions of TNBC

From: Immunotherapeutic interventions of Triple Negative Breast Cancer

Targets/types

Drug

Patient population

Recruitment

Phase

ClinicalTrials. gov ID

Clinical trials in the neoadjuvant setting

 PD-1

Pembrolizumab

TNBC

Recruiting

II

NCT03145961

III

NCT03036488

Active, not recruiting

Ib

NCT02622074

Not yet recruiting

II

NCT03289819

PDR001

TNBC

Recruiting

II

NCT02938442

 PD-L1

Atezolizumab

TNBC

Not yet recruiting

III

NCT03197935

Recruiting

III

NCT03281954

III

NCT02620280

II

NCT02530489

Durvalumab

TNBC

Recruiting

II

NCT02685059

I/II

NCT02489448

 PD-L1, PARP

Atezolizumab, Veliparib

TNBC, BRCA1/2 mutated, other BCs

Recruiting

II

NCT02849496

 VEGF-A

Bevacizumab

TNBC

Recruiting

II

NCT02456857

 EGFR

Panitumumab

TNBC

Recruiting

II

NCT02593175

TN-IBC

Recruiting

II

NCT02876107

 ACT

DC

BC

Recruiting

I/II

NCT03450044

γδ T cells

BC

Recruiting

I/II

NCT03183206

DC-CIK

BC

Active, not recruiting

II

NCT02491697

ROR1 + CAR-T cells

TNBC, BCs, Leukemia, Lymphoma

Recruiting

I

NCT02706392

 Vaccine

DC vaccine

TNBC and other BCs

Recruiting

I/II

NCT02018458

Neoantigen DNA

TNBC

Recruiting

I

NCT03199040

PVX-410

TNBC

Recruiting

I

NCT02826434

Clinical trials in the adjuvant setting

 PD-1

Pembrolizumab

TNBC

Recruiting

III

NCT03036488

TNBC and other BCs

Recruiting

III

NCT02954874

 PD-1, PARP

Pembrolizumab, Niraparib

TNBC, OC

Recruiting

I/II

NCT02657889

 ACT

NK cells

BC

Recruiting

I/II

NCT02844335

DC-CIK

TNBC, HCC, RCC, UBC, CRC, NSCLC

Recruiting

I/II

NCT02886897

 Vaccine

PVX-410

TNBC

Recruiting

I

NCT02826434

Clinical trials in the metastatic setting

 PD-1

Pembrolizumab

TNBC

Active, not recruiting

III

NCT02555657

II

NCT02447003

Recruiting

III

NCT02819518

II

NCT02768701

II

NCT02755272

I/II

NCT02734290

Ib/II

NCT01676753

Not yet recruiting

II

NCT03121352

TNBC, IBC

Not yet recruiting

II

NCT03184558

Nivolumab

TNBC

Recruiting

II

NCT03316586

II

NCT02499367

JS001

TNBC

Not yet recruiting

I

NCT03251313

Recruiting

I

NCT03151447

PDR001

TNBC, NSCLC, TC, Melanoma

Recruiting

Ib/II

NCT02404441

TNBC, CRC, NSCLC

Recruiting

I

NCT02890069

 PD-L1

Atezolizumab

TNBC

Not yet recruiting

II

NCT03164993

Active, not recruiting

III

NCT02425891

Recruiting

III

NCT03125902

Ib/II

NCT02708680

IIb

NCT01898117

Durvalumab

TNBC

Recruiting

I/II

NCT02628132

Avelumab

TNBC, SCCHN, SCLC, NSCLC, Melanoma,

Recruiting

Ib/II

NCT02554812

 CTLA-4

Tremelimumab

TNBC, UBC, PDAC

Active, not recruiting

II

NCT02527434

 PD-L1, CTLA-4

Durvalumab, Tremelimumab

TNBC, SCCHN, SCLC, GEJ, PDAC, ESCC

Recruiting

Ib

NCT02658214

 PD-1, PARP

Pembrolizumab, Niraparib

TNBC, OC

Recruiting

I/II

NCT02657889

 PD-L1, PARP

Durvalumab, Olaparib

TNBC

Recruiting

II

NCT03167619

Durvalumab, Olaparib/Cediranib

TNBC, OC, CRC, NSCLC, SCLC, CRPC

Recruiting

I/II

NCT02484404

Atezolizumab, Veliparib

TNBC, BRCA1/2 mutated, other BCs

Recruiting

II

NCT02849496

 VEGF-A

Bevacizumab

TNBC and other BCs

Active, not recruiting

II

NCT00733408

 ACT

NK cells

BC

Recruiting

I/II

NCT02843126

Anti-MUC1 CAR-T cells

TNBC, HCC, NSCLC, PC

Recruiting

I/II

NCT02587689

NKG2D CAR-T cells

TNBC, CRC, OC, UC, PC, MM

Recruiting

I/II

NCT03018405

 Vaccine

haNK cell

TNBC

Not yet recruiting

Ib/II

NCT03387085

Ib/II

NCT03175666

 ADC

IMMU-132

TNBC

Recruiting

III

NCT02574455

Not yet recruiting

II

NCT02161679

CDX-011

TNBC

Active, not recruiting

II

NCT01997333

SGN-LIV1A

TNBC

Recruiting

I

NCT01969643

 ADC, PD-1

SGN-LIV1A, Pembrolizumab

TNBC

Recruiting

Ib/II

NCT03310957